NASDAQ: NTRB
Nutriband Inc Stock Forecast, Predictions & Price Target

Analyst price target for NTRB

Based on 1 analyst offering 12 month price targets for Nutriband Inc

Min Forecast
$13.00+88.95%
Avg Forecast
$13.00+88.95%
Max Forecast
$13.00+88.95%

Should I buy or sell NTRB stock?

Based on 1 analyst offering ratings for Nutriband Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although NTRB's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates NTRB as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their NTRB stock forecasts and price targets.

NTRB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-01-22

1 of 1

Forecast return on equity

Is NTRB forecast to generate an efficient return?

Company
635.01%
Industry
142.9%
Market
80.27%
NTRB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NTRB forecast to generate an efficient return on assets?

Company
546.51%
Industry
35.65%
NTRB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NTRB earnings per share forecast

What is NTRB's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.56
Avg 2 year Forecast
$1.45
Avg 3 year Forecast
$3.66

NTRB revenue forecast

What is NTRB's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$14.1M+558.32%
Avg 2 year Forecast
$95.4M+4,359.38%
Avg 3 year Forecast
$180.4M+8,332.2%
NTRB's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NTRB revenue growth forecast

How is NTRB forecast to perform vs Biotechnology companies and vs the US market?

Company
338.01%
Industry
64.17%
Market
10.07%
NTRB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NTRB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NTRB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NTRB$6.88$13.00+88.95%Buy
IMAB$0.94$5.50+485.11%Buy
TELO$2.55N/AN/A
AVTE$2.68N/AN/A
CNTX$0.87$6.00+592.04%Strong Buy

Nutriband Stock Forecast FAQ

Is Nutriband Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: NTRB) stock is to Buy NTRB stock.

Out of 1 analyst, 0 (0%) are recommending NTRB as a Strong Buy, 1 (100%) are recommending NTRB as a Buy, 0 (0%) are recommending NTRB as a Hold, 0 (0%) are recommending NTRB as a Sell, and 0 (0%) are recommending NTRB as a Strong Sell.

If you're new to stock investing, here's how to buy Nutriband stock.

What is NTRB's earnings growth forecast for 2026-2028?

(NASDAQ: NTRB) Nutriband's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.

Nutriband's earnings in 2025 is -$10,482,617.On average, 1 Wall Street analyst forecast NTRB's earnings for 2026 to be -$6,246,336, with the lowest NTRB earnings forecast at -$6,246,336, and the highest NTRB earnings forecast at -$6,246,336. On average, 1 Wall Street analyst forecast NTRB's earnings for 2027 to be $16,173,548, with the lowest NTRB earnings forecast at $16,173,548, and the highest NTRB earnings forecast at $16,173,548.

In 2028, NTRB is forecast to generate $40,824,266 in earnings, with the lowest earnings forecast at $40,824,266 and the highest earnings forecast at $40,824,266.

What is NTRB's revenue growth forecast for 2026-2028?

(NASDAQ: NTRB) Nutriband's forecast annual revenue growth rate of 338.01% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.07%.

Nutriband's revenue in 2025 is $2,139,537.On average, 1 Wall Street analysts forecast NTRB's revenue for 2026 to be $157,106,499, with the lowest NTRB revenue forecast at $157,106,499, and the highest NTRB revenue forecast at $157,106,499. On average, 1 Wall Street analysts forecast NTRB's revenue for 2027 to be $1,064,219,455, with the lowest NTRB revenue forecast at $1,064,219,455, and the highest NTRB revenue forecast at $1,064,219,455.

In 2028, NTRB is forecast to generate $2,012,323,990 in revenue, with the lowest revenue forecast at $2,012,323,990 and the highest revenue forecast at $2,012,323,990.

What is NTRB's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: NTRB) forecast ROA is 546.51%, which is higher than the forecast US Biotechnology industry average of 35.65%.

What is NTRB's Price Target?

According to 1 Wall Street analyst that have issued a 1 year NTRB price target, the average NTRB price target is $13.00, with the highest NTRB stock price forecast at $13.00 and the lowest NTRB stock price forecast at $13.00.

The Wall Street analyst predicted that Nutriband's share price could reach $13.00 by Jan 22, 2026. The average Nutriband stock price prediction forecasts a potential upside of 88.95% from the current NTRB share price of $6.88.

What is NTRB's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: NTRB) Nutriband's current Earnings Per Share (EPS) is -$0.99. On average, analysts forecast that NTRB's EPS will be -$0.56 for 2026, with the lowest EPS forecast at -$0.56, and the highest EPS forecast at -$0.56. On average, analysts forecast that NTRB's EPS will be $1.45 for 2027, with the lowest EPS forecast at $1.45, and the highest EPS forecast at $1.45. In 2028, NTRB's EPS is forecast to hit $3.66 (min: $3.66, max: $3.66).

What is NTRB's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: NTRB) forecast ROE is 635.01%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.